Balyasny Asset Management L.P. Acquires Shares of 38,488 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Balyasny Asset Management L.P. bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 38,488 shares of the specialty pharmaceutical company's stock, valued at approximately $2,138,000. Balyasny Asset Management L.P. owned about 0.18% of ANI Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. abrdn plc purchased a new position in ANI Pharmaceuticals in the fourth quarter worth $13,155,000. Barclays PLC lifted its stake in ANI Pharmaceuticals by 1,681.2% during the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of ANI Pharmaceuticals by 67.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after purchasing an additional 125,438 shares in the last quarter. Global Alpha Capital Management Ltd. increased its position in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock valued at $34,525,000 after purchasing an additional 88,100 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $3,981,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now directly owns 89,897 shares of the company's stock, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider now directly owns 107,317 shares in the company, valued at approximately $6,487,312.65. The trade was a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,681 shares of company stock valued at $468,698. 11.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. Guggenheim reaffirmed a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ ANIP traded up $0.46 during trading hours on Friday, hitting $59.99. The company's stock had a trading volume of 372,976 shares, compared to its average volume of 297,662. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -109.07 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business has a 50-day simple moving average of $66.94 and a 200-day simple moving average of $60.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the company earned $0.82 EPS. The business's quarterly revenue was up 43.4% compared to the same quarter last year. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.